Skip to main content

Arbutus Biopharma Corp 8-K, filed Nov 10, 2026

Arbutus Biopharma Corp (ABUS)

8-K 2026-11-10 For: 2026-11-10
View Original
Added on November 10, 2026

About this 8-K

Arbutus Biopharma Corp filed this 8-K on November 10, 2026.

Arbutus Biopharma reported net income of $59.1 million for the quarter ended September 30, 2026, compared with a net loss of $7.7 million a year earlier. It completed a tender offer in early October 2026, buying 46 million shares at $5.00 per share and returning $230 million to shareholders. Cash, cash equivalents and marketable securities were $337.5 million as of September 30, 2026. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits